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Uncomplicateda b s t r a c t
Background: Single-fraction radiotherapy (SFRT) offers equal pain relief for uncomplicated painful bone
metastases as compared to multiple-fraction radiotherapy (MFRT). Despite this evidence, the adoption
of SFRT has been poor with published rates of SFRT for uncomplicated bone metastases ranging from
<10% to 70%. We aimed to evaluate the adoption of SFRT and its evolution over time following the more
formal endorsement of the international guidelines in our centre starting from 2013.
Materials and methods: We performed a retrospective review of fractionation schedules at our centre for
painful uncomplicated bone metastases from January 2013 until December 2017. Only patients treated
with 1  8 Gy (SFRT-group) or 10  3 Gy (MFRT-group) were included. We excluded other fractionation
schedules, primary cancer of the bone and post-operative radiotherapy. Uncomplicated was defined as
painful but not associated with impending fracture, existing fracture or existing neurological compres-
sion. Temporal trends in SFRT/MFRT usage and overall survival were investigated. We performed a
lesion-based patterns of care analysis and a patient-based survival analysis. Mann-Whitney U and Chi-
square test were used to assess differences between fractionation schedules and temporal trends in pre-
scription, with Kaplan-Meier estimates used for survival analysis (p-value <0.05 considered significant).
Results: Overall, 352 patients and 594 uncomplicated bone metastases met inclusion criteria. Patient
characteristics were comparable between SFRT and MFRT, except for age. Overall, SFRT was used in
92% of all metastases compared to 8% for MFRT. SFRT rates increased throughout the study period from
85% in 2013 to 95% in 2017 (p = 0.06). Re-irradiation rates were higher in patients treated with SFRT (14%)
as compared to MFRT (4%) (p = 0.046). Four-week mortality and median overall survival did not differ
significantly between SFRT and MFRT (17% vs 18%, p = 0.8 and 25 weeks vs 38 weeks, p = 0.97, respec-
tively).
Conclusions: Adherence to the international guidelines for SFRT for uncomplicated bone metastasis was
high and increased over time to 95%, which is the highest reported rate in literature.
 2021 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Bone metastases are a common manifestation of advanced can-
cer and are a significant cause of morbidity. Radiotherapy (RT) is a
proven effective treatment in the management of painful bone
metastases. Next to its analgesic effect , RT also improves quality
of life [1–5].In the past, several randomised controlled trials compared
single-fraction radiotherapy (SFRT) with multiple-fraction radio-
therapy (MFRT). They have shown equivalence in pain relief. Chow
et al. showed overall pain response (complete or partial) of 60% and
61% for SFRT and MFRT respectively [1,2]. The authors also noted
little discernible difference in toxicity. There were no significant
differences in duration of the pain relief response or overall sur-
vival reported [6–8]. Consequently, the ASTRO Evidence-Based
Guideline endorses SFRT as the treatment of choice for uncompli-
cated bone metastases [9]. Longer schedules can be considered
for complicated metastases or patients who have undergone surgi-
cal stabilization. These guidelines are considered the international
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ies indicate that longer fractionation schedules are still being over-
used with reported rates of SFRT in literature ranging from 4.1% to
70.4% [10–13]. In 2013, our department decided to more formally
implement the international guidelines. The goal of this paper is to
evaluate the temporal trends in SFRT and MFRT for uncomplicated
bone metastases over a 5-year period in a tertiary academic centre
and the survival distributions of these patients.2. Methods
2.1. Sample and data collection
We conducted a retrospective chart review of patients referred
for palliative radiotherapy for uncomplicated bone metastases
between January 1, 2013 and December 31, 2017. The following
treatment, tumour and patient factors were included: gender, age
at radiation, fractionation schedule (1  8 Gy or 10  3 Gy), patient
survival status, primary tumour, irradiated anatomical site,
retreatment rate, simultaneous extra-osseous meta, Karnofsky
score, the Number of Risk Factors (NRF) and the Recursive Parti-
tioning Analysis (RPA) [14,15]. Both NRF and RPA estimate progno-
sis. The NRF is based on three risk factors: non-breast primary
cancer, metastases other than bone and KPS  60. The RPA model
includes three variables, which are the interval between primary
diagnosis and radiotherapy for bone metastases, age and KPS. Fur-
thermore we performed an in depth review of individual files and
cases looking for reasons for guideline violations.
Following patients were excluded: primary cancer of the bone,
patients who received postoperative radiotherapy for bone metas-
tases and complicated metastases. Uncomplicated was defined as
painful but not associated with impending fracture, existing frac-
ture or existing spinal cord or cauda equina compression. For
spinal metastases we used the spinal instability neoplastic score
(SINS) [16]. A SINS between 7 and 12 was defined as an impending
fracture and higher than 12 was seen as unstable. Both were
viewed as complicated. Furthermore, spinal lesions with a SINS
lower than 7 but with existing pathologic fracture or existing
spinal cord or cauda equina compression were excluded. As were
femoral lesions with more than 3 cm axial and/or 50% circumferen-
tial cortical involvement [17].
2.2. Statistical analysis
2.2.1. Patterns of care analysis
The analyses were lesion based, patients who received more
than 1 course of RT were evaluated for each course separately.
Descriptive statistics were applied to estimate frequencies and
proportions of the SFRT and MFRT groups. Means, medians, stan-
dard deviations and ranges were reported for continuous variables.
The non-parametric Mann-Whitney U and chi-square test were
used to assess differences in proportions of respectively continu-
ous and categorical variables between fractionation schedules.
The chi-square test was carried out to determine temporal trends
in SFRT and MFRT treatments.
2.2.2. Survival analysis
The survival analysis was patient-based. If patients were irradi-
ated at two or more anatomical sites, only the lesion that was irra-
diated last was selected (594 metastases corresponding for 352
patients). To analyse differences in survival distributions, log-
rank tests were performed for the following variables: fractiona-
tion schedule, NRF, RPA and a Kaplan-Meier curve was plotted
for differences in survival between fractionation schedules. Two-
sided P values for statistical significance were set at 0.05. All anal-65yses were carried out using the IBM SPSS Statistics software ver-
sion 25.0.3. Results
3.1. Patterns of care analysis
The total data set consisted of 1041 bone metastases of which
594 were uncomplicated and met inclusion criteria. The eventual
cohort contained 352 patients irradiated for 594 bone metastases.
Table 1 gives an overview of patient and metastasis characteristics.
Overall, 91.6 percent of all metastases received a single fraction
of radiotherapy in comparison to 8.4% for multiple fractions.
Patient and metastasis characteristics between single and multiple
fractions were comparable, except for age with patients treated
with MFRT being older (table 1). The retreatment rate was higher
in patients treated with SFRT (14% vs 4%; P = 0.046). SFRT adoption
increased over the five study years from 85.5% in 2013 (99/116
cases) to 95.3% in 2017 (121/127) (Fig. 1, P = 0.055). In depth
review of individual files and cases could not identify objective rea-
sons for choosing MFRT over SFRT.
3.2. Survival analysis
Two hundred thirty-eight patients (68%) had died at the time of
the analyses. The 4-week mortality was comparable between SFRT
(17%) and MFRT (18.4%) (P = 0.8). Median overall survival was
6.5 months (95% CI 5–8) for the whole group (6.2 months for SFRT,
as compared to 9.4 months for MFRT (P = 0.978)), as seen in table 2.
Both the RPA and NRF model stratified patients in prognostic
groups following radiotherapy. Kaplan-Meier curves showing sur-
vival for NRF and RPA models are included in Fig. 2A and B.
3.3. Discussion
From 2013 to 2017, the use of SFRT increased in our depart-
ment from 85% to 95%, with a retreatment rate comparable to
reported literature [5]. Our use of SFRT exceed the ones reported
in literature, which range from 4.1% to 70.4% [11,13]. SFRT has
several advantages over MFRT including shorter treatment time
and better cost-effectiveness. Despite the published evidence
showing equal pain relief rates radiation-oncologists still seem
reluctant to implement SFRT. The factors influencing prescription
behavior can be classified into four categories relating to patient,
tumour, setting and/or oncologist [18–21]. Our retrospective
review could not reveal any tumour related factors that signifi-
cantly predicted choice of MFRT over SFRT for uncomplicated
bone metastases. In terms of patient related factors oddly enough
the MFRT-group included older patients. A reason for this could
be that, despite longer overall treatment time, the need for
retreatment was seen as too bothersome for older patients. A
third category are the setting related factors. Our hospital is
located in the Ghent metropolitan area in Belgium. Belgium is
one of the most densely populated countries in the world. Ghent
has a high linac density of about 1.25/100.000 population. This is
on par with other high income countries [22]. In countries with-
out a reimbursement per fractions there is a disincentive for the
use of MFRT in uncomplicated bone metastases. Lievens et al.
found that reimbursement modality influences the prescribed
fractionation regimen in West-European radiotherapy centers. In
budget and case payment financing a lower total number of frac-
tions and lower total dose is prescribed. Longer courses tend to be
more prescribed in countries where the remuneration depends on
the number of treatments [12,23]. In Belgium, both SFRT and
MFRT for palliation are reimbursed equally. This leads us to
Table 1
Overview of patient and metastasis characteristics.
Characteristics All uncomplicated bone metastases (n = 594) SFRT MFRT p-value
(n = 544; 91.6%) (n = 50; 8.4%)
Gender 0.593
Man 342 (57.6%) 315 (57.9%) 27 (54%)
Woman 252 (42.4%) 229 (42.1%) 23 (46%)
Age at radiation 0.008
Mean ± standard deviation 64.19 ± 13.28 62.95 ± 13.54 67.78 ± 11.16
Median (range) 66 (18–94) 64 (18–94) 69 (35–85)
Primary tumour 0.552
Prostate 120 (20.2%) 110 (20.2%) 10 (20%)
Breast 77 (13%) 69 (12.7%) 8 (16%)
Lung 153 (25.8%) 137 (25.2%) 16 (32%)
Gastro-intestinal 88 (14.8%) 84 (15.4%) 4 (8%)
Other 156 (26.3%) 144 (26.5%) 12 (24%)
Anatomical site 0.582
Axial and spinal 151 (25.6%) 136 (25.2%) 15 (30%)
Axial and non-spinal 154 (26.1%) 144 (26.7%) 10 (20%)
Non-axial 263 (44.6%) 241 (44.6%) 22 (44%)
Unspecified 22 (3.7%) 19 (3.5%) 3 (6%)
Simultaneous extra-osseous metastases 0.831
No 210 (35.3%) 194 (35.6%) 16 (32%)
Yes 383 (64.5%) 349 (64.2%) 34 (68%)
Unknown 1 (0.2%) 1 (0.2%) 0
Needed re-irradiation 0.046
No 516 (86.9%) 468 (86%) 48 (96%)
Yes 78 (13.1%) 76 (14%) 2 (4%)
Karnofsky Performance Score 0.591
Median (range) 70 (30–100) 70 (30–100) 70 (50–90)
KPS < 70 141 (33.73%) 129 (33.86%) 12 (32.43%)
KPS  70 277 (66.27%) 252 (66.14%) 25 (67.57%)
*for 176 patients no KPS.
Fig. 1. Graph showing the adoption of SFRT over the five study years.
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case. A final category are the oncologist related factors including
level of training and personal beliefs [24]. The number of patients
being treated with MFRT is too low to perform meaningful statis-
tical analyses. In depth review of individual files and cases
revealed a subjective reason for choosing MFRT in a number of
cases, leading us to believe that oncologist related factors are
the most important driver of prescription choice in our study.66Both RPA and NRF models are suggested as survival prediction
tools to objectify patient prognosis in patients with spinal bone
metastases and with general metastatic cancer, respectively. In
the current analysis, we were able to confirm the discriminative
power of these models. Four-week mortality did not differ between
treatment groups which leads us to believe that a significant por-
tion of patients with the worst prognosis did not receive SFRT.
Seven patients in the MFRT-group died within 4 weeks of the
Table 2
Univariate survival analysis.
Characteristics Number of patients (n = 352) Median overall survival (95% CI) P-value
Fractionation schedule
Number of evaluable patients 348 0.978
SFRT 310 (89.1%) 6.2 months (5–7.4)
MFRT 38 (10.9%) 9.4 months (6–12.9)
RPA*
All patients
Number of evaluable patients 298 <0.001
Class 1 43 (14.4%) 29.5 months (7.2–51.75)
Class 2 200 (67.1%) 4.8 months (3.18–6.4)
Class 3 55 (18.5%) 3.65 months (0.1–7.21)
NRF*
Number of evaluable patients 241 <0.001
0 risk factors 14 (5.8%) Not reached
1 risk factor 54 (22.4%) 11.1 months (0–24.58)
2 risk factors 118 (49%) 4.04 months (1.32–6.75)
3 risk factors 55 (22.8%) 2.23 months (1.13–3.33)
Died within 4 weeks of RT 0.825
All patients /








Number of evaluable patients 38
Yes 7 (18.4%)
No 31 (81.6%)
*RPA: recursive partitioning analysis index; NRF: number of risk factors.
Log-rank test was used.
Fig. 2. (A) Kaplan-Meier reporting time between radiotherapy and death stratified per NRF. (B) Kaplan-Meier reporting time between radiotherapy and death stratified per
RPA.
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enough to enjoy any treatment effect.
There are several limitations of our study. The first being its ret-
rospective nature. This meant there was no standardised way of
assessing patients’ pain response. As such pain response wasn’t
reported. The retrospective nature also limited our ability to thor-67oughly examine prescription behavior. Prospectively collected data
could have included questionnaires that would help us understand
the rationale of choosing MFRT in uncomplicated bone metastases.
Because of the high uptake of SFRT in our centre the MFRT groups
consisted of only 50 metastases. This limited our ability to find fac-
tors that drove further prescription of longer courses. The past few
Fig. 2 (continued)
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ease namely SBRT [25–27]. Our review only looked at 1  8Gy and
10  3Gy schedules. As such any other schedule, including for oli-
gometastatic disease, were excluded.4. Conclusion
Adherence to the international guidelines for SFRT for uncom-
plicated bone metastasis was high and increased over time to
95%, which is the highest reported rate in literature.Declaration of Competing Interest
The authors declare that they have no known competing finan-
cial interests or personal relationships that could have appeared
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